Compare · COR vs SCNX
COR vs SCNX
Side-by-side comparison of Cencora Inc. (COR) and Scienture Holdings Inc. (SCNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COR and SCNX operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- COR is the larger of the two at $62.60B, about 3689.5x SCNX ($17.0M).
- COR has been more active in the news (10 items in the past 4 weeks vs 4 for SCNX).
- COR has more recent analyst coverage (25 ratings vs 0 for SCNX).
- Company
- Cencora Inc.
- Scienture Holdings Inc.
- Price
- -
- -
- Market cap
- $62.60B
- $17.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 10
- 4
- Recent ratings
- 25
- 0
Cencora Inc.
CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options  all of which leads to a best-in-class customer experience and lasting relationships.
Latest COR
- Executive Vice President Campbell Elizabeth S sold $3,662,663 worth of shares (11,300 units at $324.12), decreasing direct ownership by 37% to 19,455 units (SEC Form 4)
- RBC Capital Mkts initiated coverage on Cencora with a new price target
- Cencora Inc. filed SEC Form 8-K: Regulation FD Disclosure
- SEC Form 10-Q filed by Cencora Inc.
- Cencora Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Cencora Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Cencora Reports Fiscal 2026 Third Quarter Results
- Director Nally Dennis M was granted 113 shares, increasing direct ownership by 0.86% to 13,188 units (SEC Form 4)
- Director Cooper Ellen was granted 97 shares, increasing direct ownership by 12% to 893 units (SEC Form 4)
- Director Tyler Lauren M was granted 97 shares, increasing direct ownership by 2% to 4,456 units (SEC Form 4)
Latest SCNX
- Scienture Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
- SEC Form 10-Q filed by Scienture Holdings Inc.
- SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
- SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
- SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
- SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
- SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
- SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
- Scienture Holdings Inc. filed SEC Form 8-K: Leadership Update